We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
RENT | Rent the Runway Inc | 11.42 | 4.02 | 54.32% | 1,923,874 |
ALPN | Alpine Immune Sciences Inc | 64.32 | 17.28 | 36.73% | 4,116,930 |
RLYB | Rallybio Holdings LLC | 2.20 | 0.57 | 34.97% | 1,292,993 |
EFOI | Energy Focus Inc | 2.04 | 0.44 | 27.50% | 218,287 |
TC | TuanChe Ltd | 2.06 | 0.26 | 14.44% | 13,850 |
KAVL | Kaival Brands Innovations Group Inc | 2.95 | 0.30 | 11.32% | 2,791 |
VERB | Verb Technology Company Inc | 0.2025 | 0.0205 | 11.26% | 933,417 |
VERA | Vera Therapeutics Inc | 46.00 | 4.38 | 10.52% | 277,791 |
ISPO | Inspirato Inc | 4.35 | 0.38 | 9.57% | 1,539 |
ENTX | Entera Bio Ltd | 2.43 | 0.20 | 8.97% | 3,898 |
NITO | N2OFF Inc | 1.50 | 0.11 | 7.91% | 136,117 |
Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing2, thereby eliminating the risk of FNAIT and its potentially devastating consequences in their fetuses and newborns. Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant individuals at higher risk of alloimmunization and FNAIT in the second half of 2024.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
HANGZHOU, China, April 8, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, announced today that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission ("SEC") on April 8, 2024. The annual report can be accessed on the Company's investor relations website at https://ir.nano.cn as well as the SEC's website at http://www.sec.gov.
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 69,754.11 | 639.15 | 0.92% | 1.37T | 5,682,810,770 |
ETH | Ethereum | 3,506.81 | 1.36 | 0.04% | 421.68B | 2,854,085,930 |
USDT | Tether USD | 0.99981 | 0.00021 | 0.02% | 97.82B | 241,764,023 |
BNB | Binance Coin | 605.30 | 24.81 | 4.27% | 95.43B | 607,779,664 |
SOL | Solana | 170.82 | -1.44 | -0.84% | 75.46B | 1,363,010,043 |
STETH | stETH | 3,494.41 | -4.38 | -0.13% | 34.29B | 4,565,339 |
XRP | Ripple | 0.6139 | -0.0001 | -0.02% | 33.52B | 500,599,802 |
DOGE | Dogecoin | 0.19846 | 0.00943 | 4.99% | 28.33B | 1,020,025,201 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 776,422,733 |
TONCOIN | Wrapped TON Coin | 6.69 | 0.011344 | 0.17% | 23.21B | 289,054,136 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions